Drug-Related Problems in Hospitalised Kidney Disease Patients V.1

  • Research type

    Research Study

  • Full title

    DRUG-RELATED PROBLEMS IN HOSPITALISED PATIENTS WITH CHRONIC KIDNEY DISEASE

  • IRAS ID

    255258

  • Contact name

    Anthony Cox

  • Contact email

    a.r.cox@bham.ac.uk

  • Sponsor organisation

    University of Birmingham

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    All in-hospital patients are at risk of drug-related problems throughout their stay in hospital, with published rates from 63% to 81%. The resultant morbidity will increase length of hospital stay and treatment costs, as well as affect the quality of life of patients, and a subset of patients will die from Drug-related problems. Patients with chronic kidney disease commonly have multiple comorbidities and are prescribed multiple drugs, increasing their risk of Drug-related problems. Our systematic review of Drug-related problems in chronic kidney disease patients has reported that Drug-related problems are common in chronic kidney disease patients, but the current published data is of relatively poor quality. The first part of our study is designed to provide reliable UK data on Drug-related problems in chronic kidney disease patients admitted to a hospital.\n\nThe use of medicines within a hospital is a complex process, which includes prescribing, dispensing, and administration – all of which have the potential for human error. These processes involve multiple professionals, with doctors, nurses, and pharmacists playing specialist roles within the team. This includes recognising, monitoring, and resolving of Drug-related problems, as well as preventing future Drug-related problems by the careful use of medicines. Implementation of checking systems on prescribing, dispensing, and administration, and other such interventions have suggested several good outcomes on patient safety. However, translation of this to practice is unclear. The second part of this research is therefore to explore the awareness and experience of HCPs in relation to the management of drug therapy in chronic kidney disease. \n\nThis study will utilise a mixed method quantitative and qualitative approach through two phases. This will include a prospective observational study reviewing chronic kidney disease patients’ records to detect any drug related problems and a qualitative interview with healthcare professionals (physicians, nurses and pharmacists). The results of this research may help in elaborating the extent of this problem, illustrate problems in current clinical practice, highlight best practice, and reduce the burden of Drug-related problems on both patients and the NHS.\n

  • REC name

    North of Scotland Research Ethics Committee 2

  • REC reference

    20/NS/0116

  • Date of REC Opinion

    2 Nov 2020

  • REC opinion

    Further Information Favourable Opinion